Core Viewpoint - The stock of CSPC Pharmaceutical Group (01093) has increased by over 4%, reaching HKD 8.36 with a trading volume of HKD 579 million, following the announcement of positive results from a Phase III clinical trial for its biosimilar drug, Sichuqi You Injection [1] Group 1: Clinical Trial Results - CSPC's subsidiary, CSPC Zhongqi Biopharmaceutical Co., Ltd., announced that its drug, Sichuqi You Injection, achieved positive topline results in a Phase III clinical trial for treating moderate to severe plaque psoriasis [1] - The study met its primary endpoint, demonstrating clinical equivalence to the reference drug, Cosentyx, with good safety profiles and no new or unexpected safety signals [1] - The drug is a fully human IgG1 monoclonal antibody and is expected to meet long-term safety needs for patients [1] Group 2: Product Background - Sichuqi You Injection is a biosimilar to Cosentyx, which has been approved in China for indications including plaque psoriasis in patients aged 6 and above, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa [1] - The efficacy and safety of Cosentyx have been widely recognized in the medical community [1]

Core Viewpoint - The stock of CSPC Pharmaceutical Group (01093) has increased by over 4%, currently trading at HKD 8.36 with a transaction volume of HKD 579 million, following the announcement of positive results from a Phase III clinical trial for its biosimilar drug, Secukinumab Injection [1] Group 1: Clinical Trial Results - CSPC's subsidiary, CSPC Zhongqi Pharmaceutical Co., Ltd., has developed Secukinumab Injection, which has shown clinical equivalence to the reference drug in a Phase III trial for moderate to severe plaque psoriasis [1] - The key study achieved its primary endpoint and demonstrated positive topline results, indicating that the product is clinically equivalent to the reference drug with good safety profiles [1] - No new or unexpected safety signals were reported, suggesting that the product may meet long-term safety requirements for patients [1] Group 2: Product Information - Secukinumab Injection is a fully human IgG1 monoclonal antibody and is a biosimilar to Cosentyx, which has been approved in China for indications including plaque psoriasis in patients aged 6 and above, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa [1] - The efficacy and safety of Cosentyx have been widely recognized, supporting the potential market acceptance of the biosimilar [1]

Company News - Emperor Capital (00717.HK) reported total revenue of approximately HKD 730 million for the year ending September 30, 2025, representing a year-on-year increase of 37.3%. Net profit reached approximately HKD 147 million, up 121.4% year-on-year [2] - New Special Energy (01799.HK) plans to sell a 79.92% stake in Xinjiang Wind Power New Energy Partnership for approximately HKD 1.337 billion to facilitate a REITs issuance [2] - Bay Area Development (00737.HK) signed a construction contract for the Shenzhen section with a contract value of RMB 1.448 billion [2] - Weichai Power (03393.HK) won a bid for the Brazil CPFL project with a contract amount exceeding HKD 80 million [3] - WuXi AppTec (02359.HK) invested approximately EUR 30 million to acquire a 3.22% stake in a French biopharmaceutical fund [3] - Joy Spreader Group (02473.HK) established a long-term strategic cooperation with New Stone Technology in areas such as autonomous vehicle procurement and market promotion [3] - Fosun Pharma (02196.HK) signed a cooperation and option agreement with Clavis Bio to jointly advance preclinical development of selected target compounds [3] - CSPC Pharmaceutical Group (01093.HK) reported top-line analysis data from the Phase III clinical trial of its drug, Truxima [3] - Yihai International (01662.HK) announced a strategic cooperation between Trio AI and HGC [4] Financing and Buyback Activities - Zhi Yuan Holdings (00990.HK) plans to issue a total of 515 million new shares at a discount of approximately 1.4%, aiming to raise about HKD 355.3 million [5] - Tencent Holdings (00700.HK) repurchased 1.055 million shares for HKD 636 million, with buyback prices ranging from HKD 599.5 to HKD 605.5 [5] - Xiaomi Group-W (01810.HK) repurchased 3.75 million shares for HKD 151 million, with buyback prices between HKD 40.12 and HKD 40.24 [6] - COSCO Shipping Holdings (01919.HK) repurchased 5.9 million shares for HKD 80.6 million, with buyback prices from HKD 13.52 to HKD 13.76 [7] - Kuaishou-W (01024.HK) repurchased 1.235 million shares for HKD 80.2 million, with buyback prices ranging from HKD 64.35 to HKD 65.60 [7] - Geely Automobile (00175.HK) repurchased 1.908 million shares for HKD 31.8 million, with buyback prices between HKD 16.26 and HKD 16.8 [8]

Core Viewpoint - The announcement highlights the successful top-line analysis data from a Phase III clinical trial of the drug Secukinumab Injection, developed by the subsidiary of the company, for the treatment of moderate to severe plaque psoriasis, indicating its clinical equivalence to an existing treatment [1][2] Group 1: Product Development - The product is a fully human IgG1 monoclonal antibody drug, serving as a biosimilar to Cosentyx, which has been approved in China for multiple indications including plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa [1] - The company follows the research guidelines for biosimilars and conducted a head-to-head equivalence study to validate the product's efficacy against Cosentyx in treating moderate to severe plaque psoriasis [2] Group 2: Clinical Trial Details - The Phase III clinical trial was a multicenter, randomized, double-blind, parallel, positive-controlled study, aimed at verifying the consistency of treatment efficacy between the product and Cosentyx [2] - The trial enrolled patients with moderate to severe plaque psoriasis, randomly assigning them in a 1:1 ratio to either the test group (the product) or the control group (Cosentyx), with the primary endpoint being the proportion of patients achieving a 75% improvement in the Psoriasis Area and Severity Index (PASI) score by week 12 [2] - The key study achieved its pre-set primary endpoint, demonstrating clinical equivalence to Cosentyx, with good safety profiles and no new or unexpected safety signals, indicating potential for long-term patient safety [2]

Core Viewpoint - The company announced that its subsidiary, Stone Pharma Biotech Co., Ltd., has achieved positive topline analysis data from a Phase III clinical trial for its drug, Secukinumab Injection, aimed at treating moderate to severe plaque psoriasis [1][2] Group 1: Product Development - Secukinumab Injection is a fully human IgG1 monoclonal antibody that specifically binds to IL-17A, a key molecule in the pathogenesis of psoriasis, thereby inhibiting inflammatory signals [1] - The product is a biosimilar to Cosentyx® (Secukinumab), which has been approved in China for multiple indications including plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa [1] Group 2: Clinical Trial Details - The clinical trial was a multicenter, randomized, double-blind, parallel, positive-controlled equivalence study designed to verify the consistency of efficacy between Secukinumab Injection and Cosentyx® in treating moderate to severe plaque psoriasis [2] - The study enrolled patients with moderate to severe plaque psoriasis, randomly assigning them in a 1:1 ratio to either the trial group (Secukinumab Injection) or the control group (Cosentyx®) [2] - The primary endpoint was the proportion of patients achieving a 75% improvement in the Psoriasis Area and Severity Index (PASI-75) score from baseline at week 12, which the study successfully met [2] Group 3: Safety and Future Plans - The study demonstrated clinical equivalence between the two products, with good safety profiles and no new or unexpected safety signals, indicating potential for long-term safety in patients [2] - Detailed data from the study will be presented at upcoming academic conferences and published in journals [2]

Core Viewpoint - The company announced that its subsidiary, Stone Pharma, has achieved positive topline results in a Phase III clinical trial for its biosimilar drug, Secukinumab injection, aimed at treating moderate to severe plaque psoriasis [1][2] Group 1: Product Development and Clinical Trials - The product, Secukinumab injection, is a fully human IgG1 monoclonal antibody that specifically binds to IL-17A, a key molecule in the pathogenesis of psoriasis [1] - The Phase III clinical trial was a multicenter, randomized, double-blind, parallel, positive-controlled equivalence study designed to verify the consistency of efficacy between the product and Cosentyx in treating moderate to severe plaque psoriasis patients [2] - The primary endpoint of the study was the proportion of patients achieving a 75% improvement in the Psoriasis Area and Severity Index (PASI-75) score from baseline at week 12, which the study successfully met [2] Group 2: Market Context and Patient Impact - There are over 7 million psoriasis patients in China, highlighting a significant market opportunity for effective treatments [1] - The safety profile of the product was found to be good, with no new or unexpected safety signals, indicating it may meet the long-term safety needs of patients [2] - The detailed data from the study will be published in upcoming academic conferences and journals, which may further validate the product's efficacy and safety [2]

Group 1 - New Horizon (300765.SZ) announced that its subsidiary, Giant Stone Biopharmaceutical Co., Ltd., has obtained topline analysis data from the Phase III clinical trial of its drug, Secukinumab injection, which is a fully human IgG1 monoclonal antibody and a biosimilar to Cosentyx® [1][2] - Secukinumab is approved in China for indications including plaque psoriasis for patients aged 6 and above, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa, with its efficacy and safety widely recognized [1] - Psoriasis is a chronic, inflammatory, systemic disease related to the immune system, with approximately 7 million patients in China. The drug specifically binds to IL-17A, a key molecule in the pathogenesis of psoriasis, blocking IL-17 receptor signaling to suppress inflammation [1] Group 2 - The development of Secukinumab follows the research guidelines for biosimilars, and a head-to-head equivalence study was conducted against Cosentyx® [2] - This study is a multicenter, randomized, double-blind, parallel, positive-controlled Phase III clinical trial aimed at verifying the consistency of efficacy between Secukinumab and Cosentyx® in treating moderate to severe plaque psoriasis patients [2] - The primary endpoint was the proportion of patients achieving a 75% improvement in the Psoriasis Area and Severity Index (PASI-75) score from baseline by week 12. The study met its primary endpoint, demonstrating clinical equivalence and good safety profile without new or unexpected safety signals, indicating potential for long-term safety in patients [2]

Core Viewpoint - New Horizon (300765.SZ) announced that its subsidiary, Giant Biopharmaceutical Co., Ltd., has achieved positive topline results in the Phase III clinical trial of its drug, Tislelizumab injection, demonstrating clinical equivalence to the reference drug, Cosentyx [1] Group 1: Product Development - The drug Tislelizumab is a fully human IgG1 monoclonal antibody and a biosimilar to Cosentyx [1] - Cosentyx has been approved in China for indications including plaque psoriasis in patients aged 6 and above, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa [1] Group 2: Clinical Trial Results - The key study met its predefined primary endpoint and showed positive topline results [1] - Statistical analysis indicates that Tislelizumab has clinical equivalence to Cosentyx, with good safety profiles and no new or unexpected safety signals [1] - The drug is expected to meet the long-term safety needs of patients [1]

Core Viewpoint - The announcement from XinNuoWei (300765.SZ) indicates that its subsidiary, Giant Biopharmaceutical Co., Ltd., has achieved positive topline results in a Phase III clinical trial for its drug, a biosimilar to Cosentyx, which is expected to meet long-term safety requirements for patients [1] Group 1: Product Development - The drug developed by Giant Biopharmaceutical is a fully human IgG1 monoclonal antibody injection [1] - The biosimilar is designed to treat conditions including plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa, which have been widely recognized for their efficacy and safety [1] Group 2: Clinical Trial Results - The key study has met its predefined primary endpoint, demonstrating clinical equivalence to Cosentyx [1] - Safety analysis showed no new or unexpected safety signals, indicating a favorable safety profile for the drug [1] - Detailed data from the trial will be presented at upcoming academic conferences and in journals [1]

Core Viewpoint - The announcement from XinNuoWei indicates that its subsidiary, Jushi Biopharma, has achieved top-line analysis data from the Phase III clinical trial of its drug, Secukinumab injection, which is a fully human IgG1 monoclonal antibody and a biosimilar to Cosentyx [1] Group 1: Product Development - Secukinumab is developed as a biosimilar to Cosentyx, which has been approved in China for treating plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa [1] - The efficacy and safety of Cosentyx have been widely recognized in the medical community [1] Group 2: Market Context - Psoriasis is a chronic, inflammatory, systemic disease related to the immune system, with approximately 7 million patients suffering from psoriasis in China [1] - Interleukin (IL)-17A, primarily produced by activated T cells, is a key molecule in the pathogenesis of psoriasis [1] Group 3: Mechanism of Action - Secukinumab specifically binds to IL-17A, blocking the signaling of the IL-17 receptor, thereby inhibiting the inflammation associated with psoriasis [1]